NASDAQ: TMDX · Medical Devices

TransMedics Group (TMDX) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values TransMedics Group (TMDX) at $102.39 a share. The stock last closed at $92.21, which puts the model's fair value 11.0% above the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. TransMedics Group, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$102.39midpoint of 2,000 simulations
Last close$92.21NASDAQ: TMDX
Gap to fair value+11.0%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $93.55 to $102.39 (+9.4%). Analysts raised their next-twelve-month EBITDA estimates: most of the move.

What the model makes of itThe price of $92.21 is 11.0% below it: Fairly valued, on a medium evidence grade.

What's nextNext report on 23 Feb 2027. Options prices imply a move of about 15% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give TMDX?

The calibrated range for TMDX over 63 trading days is $77.49 to $110.70. It sits around the last close, and its width comes from the volatility that TMDX's own options imply (53% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $76.66 to $134.76. In 62% of the simulations the fair value came out above the price the model ran on.

$51.93$195.47
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $102.39. Dashed line: the last close, $92.21.

Faircurve Insights · 14 Nov 2026

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise in Healthcare and Medical Devices. It is committed to transforming organ transplant therapy for patients worldwide with end-stage organ failure.

On 14 Nov 2026, the model's fair value was $102.39 a share, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $93.55, so the fair value moved +9.4%. In the model's words: Analysts raised their next-twelve-month EBITDA estimates: most of the move. The 63-day calibrated range is $76.71 to $109.81. Ranges built this way held the price 60% of the time at this horizon, across 8,038 past valuations refreshed on 14 Nov 2026. The model grades the evidence Medium. The grade covers input completeness, the comparable companies and how closely they agree, and the spread of outcomes. It does not say whether the fair value is right.

The model's overall quality score for the business is 49 out of 100, a composite of six quality factors scored against comparable companies. Three factors stand out. Growth quality scores 94, with trailing revenue growth of 37.1% against a peer median of 13.6%. Stability scores 0, with five-year EBITDA margin downside volatility of 46.2 points against a peer median of 4.7 points. Balance sheet scores 24, with net debt to EBITDA of 2.69x against a peer median of 0.13x. The model compares the company with Neogen Corporation (NEOG), UFP Technologies, Inc. (UFPT), Integer Holdings Corporation (ITGR), LivaNova PLC (LIVN), Haemonetics Corporation (HAE) and Enovis Corporation (ENOV).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does TMDX report earnings, and how has the stock reacted?

TransMedics Group's next earnings report is scheduled for 23 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 7.3% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. TMDX's 30 day implied volatility works out to about 15.2% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across TMDX's last 8 reports, ignoring direction, was 5.4%.

0%10%20%30%25.2%3.5%27 Feb '2519.3%13.5%30 Jul '2518.8%4.7%29 Oct '2518.1%2.1%24 Feb '2615.5%24.9%5 May '2618.4%6.2%4 Aug '2616.9%2.4%4 Nov '2617.7%21.3%5 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in TMDX

10%15%20%25%30%5 Nov '26 report4 Nov '26 report4 Aug '26 report5 May '26 report24 Feb '26 report15% at 16 Nov '2614 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 17% on 14 Nov 2025, reached 28% on 24 Jul 2026 and reads 15% on 16 Nov 2026. The marks are report dates.

How does TMDX score on business quality?

TransMedics Group's overall quality score is 49 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.669.3%ROIC5.7%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).260.31xFCF / net income1.29x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.9437.1%Revenue growth, trailing13.6%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.290.0%Net buybacks / market value2.3%
Balance sheetNet debt to EBITDA and interest coverage.242.69xNet debt / EBITDA0.13x
StabilityDownside volatility of the EBITDA margin over the last five years.046.2 ptsEBITDA margin downside volatility, 5y4.7 pts

How does TMDX compare with similar companies?

The companies in medical devices closest to TransMedics Group in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
NEOG Neogen Corporation$10.88$10.11-7.1%Fairly valued
UFPT UFP Technologies, Inc.$298.54$266.65-10.7%Fairly valued
ITGR Integer Holdings Corporation$126.97$153.83+21.2%Undervalued
LIVN LivaNova PLC$92.44$101.82+10.1%Fairly valued
HAE Haemonetics Corporation$121.34$120.83-0.4%Fairly valued
INSP Inspire Medical Systems, Inc.$59.12$61.27+3.6%Low evidence grade
ENOV Enovis Corporation$27.92$32.77+17.4%Undervalued
CNMD CONMED Corporation$49.35$50.43+2.2%Low evidence grade

What the comparable companies' multiples alone would give for TMDX, the peer-implied price, is $142.65 a share on this run. The fair value weighs that against the company's own multiple.

All medical device stocks ranked by gap to fair value

TransMedics Group at a glance

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure.

Market value
$3.2B
Sector
Healthcare
Industry
Medical Devices
Revenue expected, next twelve months
$886M
Consensus revenue growth, next fiscal year
+27.1%
Analysts with estimates
7
Beta to the US market
1.23
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. TMDX was among them.

How the fair value is worked out: the model prices TransMedics Group on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for TMDX was $93.55. As of 14 Nov 2026 it is $102.39, a change of +9.4%. Analysts raised their next-twelve-month EBITDA estimates: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about TransMedics Group's valuation

Is TransMedics Group stock undervalued or overvalued?

On Faircurve's model, TMDX reads as Fairly valued as of 14 Nov 2026. The model's fair value is $102.39 a share against a last close of $92.21, a gap of +11.0%.

What is TMDX's fair value?

$102.39 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $76.66 to $134.76.

What price range does the model give TMDX?

$77.49 to $110.70 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does TransMedics Group report earnings next?

The next report is scheduled for 23 Feb 2027. Companies can move their dates.

How much has TMDX moved on past earnings reports?

Across its last 8 reports the median two session move was 5.4%, ignoring direction. The largest was -24.9% around the report of 5 May 2026.

How confident is the model in this valuation?

The model's evidence grade for TMDX is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on TMDX

The model holds no idea open on TMDX today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on TMDX with their outcomes. A free account is enough.

Keep reading